FRANKFURT, Oct 31 (Reuters) - Sanofi-Aventis wants to double its vaccine business in the next five years, its chief executive told a German newspaper on Saturday.
'We want to double it in the next five years. Its share in group sales will increase as a result from 10-11 percent to 15-16 percent,' Chris Viehbacher told Frankfurter Allgemeine Zeitung.
He said this was one of the reasons Sanofi-Aventis had bought a company in India, which has new vaccines, such as against cholera, in the pipeline.
There is also an enormous potential in Asia, he added. Keywords: SANOFIAVENTIS/ (Reporting by Marilyn Gerlach; Reuters Messaging: marilyn.gerlach.reuters.com@reuters.net; 00 49 69 7565 1279) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
'We want to double it in the next five years. Its share in group sales will increase as a result from 10-11 percent to 15-16 percent,' Chris Viehbacher told Frankfurter Allgemeine Zeitung.
He said this was one of the reasons Sanofi-Aventis had bought a company in India, which has new vaccines, such as against cholera, in the pipeline.
There is also an enormous potential in Asia, he added. Keywords: SANOFIAVENTIS/ (Reporting by Marilyn Gerlach; Reuters Messaging: marilyn.gerlach.reuters.com@reuters.net; 00 49 69 7565 1279) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
